These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28801680)

  • 1. Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B.
    Bi J; Li X; Liu J; Chen D; Li S; Hou J; Zhou Y; Zhu S; Zhao Z; Qin E; Wei Z
    Sci Rep; 2017 Aug; 7(1):7893. PubMed ID: 28801680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
    Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
    Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.
    Schwarz KB; Mohan P; Narkewicz MR; Molleston JP; Nash SR; Hu S; Wang K; Gries JM
    J Pediatr Gastroenterol Nutr; 2006 Oct; 43(4):499-505. PubMed ID: 17033526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C.
    Xu C; Gupta S; Krishna G; Cutler D; Wirth S; Galoppo C; Ciocca M; Kolz K; Noviello S; Sniukiene V
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2045-54. PubMed ID: 23975236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.
    Charatcharoenwitthaya P; Sukeepaisarnjaroen W; Piratvisuth T; Thongsawat S; Sanpajit T; Chonprasertsuk S; Jeamsripong W; Sripariwuth E; Komolmit P; Patcharatrakul T; Boonsirichan R; Bunchorntavakul C; Tuntipanichteerakul S; Tanwandee T;
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1874-1881. PubMed ID: 26997582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
    Suh DJ; Lee HC; Byun KS; Cho M; Kweon YO; Tak WY; Chon CY; Koh KC; Lee YS
    Antivir Ther; 2013; 18(6):765-73. PubMed ID: 23900457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS.
    Morcos PN; Leong R; Thommes JA; DePamphilis J; Grippo JF; Brennan BJ
    Hepatogastroenterology; 2015; 62(137):11-8. PubMed ID: 25911859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a.
    Lamb MW; Martin NE
    Ann Pharmacother; 2002 May; 36(5):933-5. PubMed ID: 12014351
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection.
    Colvin RA; Tanwandee T; Piratvisuth T; Thongsawat S; Hui AJ; Zhang H; Ren H; Chen PJ; Chuang WL; Sobhonslidsuk A; Li R; Qi Y; Praestgaard J; Han Y; Xu J; Stein DS;
    J Gastroenterol Hepatol; 2015 Jan; 30(1):184-91. PubMed ID: 24995515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B.
    Hui CK; Lau GK
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):495-504. PubMed ID: 16107195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pegylated alfa-2a in hepatitis B. Fewer injections with better results?].
    MMW Fortschr Med; 2003 Nov; 145(48):63. PubMed ID: 14725009
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.
    Tangkijvanich P; Chittmittraprap S; Poovorawan K; Limothai U; Khlaiphuengsin A; Chuaypen N; Wisedopas N; Poovorawan Y
    J Viral Hepat; 2016 Jun; 23(6):427-38. PubMed ID: 26387494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: an observational, multicenter, open label, non-interventional study in Turkish patients.
    Tözün N; Sezgın O; Gülşen M; Kacar S; Yenıce N; Yilmaz Ş; Hülagü S; Kantarçeken B; Yakaryilmaz F; Yurcı A; Serez KM; Bahçecıoğlu H; Bağci S
    Turk J Gastroenterol; 2012; 23(5):552-9. PubMed ID: 23161301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.